{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:58:38Z","timestamp":1771952318121,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06858-9","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T08:56:24Z","timestamp":1770195384000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Burixafor, a CXCR4 inhibitor with a differentiated kinetics profile: results of a phase 2 study for rapid cell mobilization in multiple myeloma and lymphoma patients undergoing transplant"],"prefix":"10.1007","volume":"105","author":[{"given":"Devki D.","family":"Sukhtankar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pina M.","family":"Cardarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bita","family":"Jalilizeinali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gayatri","family":"Setia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"GaYeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-wen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-yuan","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ni\u00f1a G.","family":"Caculitan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael W.","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"key":"6858_CR1","doi-asserted-by":"crossref","unstructured":"Worel N, Bilgin YM, Wuchter P (2024) The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies. In: Sureda A (ed) The EBMT handbook: hematopoietic cell transplantation and cellular therapies. pp 151\u2013157","DOI":"10.1007\/978-3-031-44080-9_16"},{"key":"6858_CR2","doi-asserted-by":"publisher","DOI":"10.1177\/20406207231174304","volume":"14","author":"ZD Crees","year":"2023","unstructured":"Crees ZD, Rettig MP, DiPersio JF (2023) Innovations in hematopoietic stem-cell mobilization: a review of the novel CXCR4 inhibitor motixafortide. Ther Adv Hematol 14:20406207231174304. https:\/\/doi.org\/10.1177\/20406207231174304","journal-title":"Ther Adv Hematol"},{"key":"6858_CR3","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1159\/000088410","volume":"114","author":"N Flomenberg","year":"2005","unstructured":"Flomenberg N, DiPersio J, Calandra G (2005) Role of CXCR4 chemokine receptor blockade using AMD3100 for mobilization of autologous hematopoietic progenitor cells. Acta Haematol 114:198\u2013205. https:\/\/doi.org\/10.1159\/000088410","journal-title":"Acta Haematol"},{"key":"6858_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cells12242855","author":"SM Alnasser","year":"2023","unstructured":"Alnasser SM, Alharbi KS, Almutairy AF, Almutairi SM, Alolayan AM (2023) Autologous stem cell transplant in Hodgkin\u2019s and non-Hodgkin\u2019s lymphoma, multiple myeloma, and AL amyloidosis. Cells. https:\/\/doi.org\/10.3390\/cells12242855","journal-title":"Cells"},{"key":"6858_CR5","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1001\/jamaoncol.2017.4600","volume":"4","author":"B Dhakal","year":"2018","unstructured":"Dhakal B et al (2018) Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction: a systematic review and meta-analysis. JAMA Oncol 4:343\u2013350. https:\/\/doi.org\/10.1001\/jamaoncol.2017.4600","journal-title":"JAMA Oncol"},{"key":"6858_CR6","doi-asserted-by":"publisher","first-page":"e497","DOI":"10.3324\/haematol.2019.236182","volume":"105","author":"N Uchida","year":"2020","unstructured":"Uchida N et al (2020) Safe and efficient peripheral blood stem cell collection in patients with sickle cell disease using plerixafor. Haematologica 105:e497. https:\/\/doi.org\/10.3324\/haematol.2019.236182","journal-title":"Haematologica"},{"key":"6858_CR7","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2147\/TACG.S178546","volume":"12","author":"G Karponi","year":"2019","unstructured":"Karponi G, Zogas N (2019) Gene therapy for Beta-Thalassemia: updated perspectives. Appl Clin Genet 12:167\u2013180. https:\/\/doi.org\/10.2147\/TACG.S178546","journal-title":"Appl Clin Genet"},{"key":"6858_CR8","doi-asserted-by":"publisher","first-page":"e38036","DOI":"10.1097\/MD.0000000000038036","volume":"103","author":"J Hu","year":"2024","unstructured":"Hu J et al (2024) beta-Thalassemia gene editing therapy: advancements and difficulties. Med (Baltim) 103:e38036. https:\/\/doi.org\/10.1097\/MD.0000000000038036","journal-title":"Med (Baltim)"},{"key":"6858_CR9","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2024.19462","volume":"332","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Maus MV, Hinrichs CS (2024) CAR t cells and T-cell therapies for cancer: a translational science review. JAMA 332:1924\u20131935. https:\/\/doi.org\/10.1001\/jama.2024.19462","journal-title":"JAMA"},{"key":"6858_CR10","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1200\/JCO.2004.07.131","volume":"22","author":"SM Devine","year":"2004","unstructured":"Devine SM et al (2004) Rapid mobilization of CD34+\u2009cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin\u2019s lymphoma. J Clin Oncol 22:1095\u20131102. https:\/\/doi.org\/10.1200\/JCO.2004.07.131","journal-title":"J Clin Oncol"},{"key":"6858_CR11","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1200\/JCO.1995.13.6.1328","volume":"13","author":"J Beyer","year":"1995","unstructured":"Beyer J et al (1995) Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison. J Clin Oncol 13:1328\u20131335. https:\/\/doi.org\/10.1200\/JCO.1995.13.6.1328","journal-title":"J Clin Oncol"},{"key":"6858_CR12","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1537-2995.2005.04222.x","volume":"45","author":"WC Liles","year":"2005","unstructured":"Liles WC et al (2005) Augmented mobilization and collection of CD34+\u2009hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion 45:295\u2013300. https:\/\/doi.org\/10.1111\/j.1537-2995.2005.04222.x","journal-title":"Transfusion"},{"key":"6858_CR13","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/s41591-023-02273-z","volume":"29","author":"ZD Crees","year":"2023","unstructured":"Crees ZD et al (2023) Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial. Nat Med 29:869\u2013879. https:\/\/doi.org\/10.1038\/s41591-023-02273-z","journal-title":"Nat Med"},{"key":"6858_CR14","doi-asserted-by":"publisher","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","volume":"113","author":"JF DiPersio","year":"2009","unstructured":"DiPersio JF et al (2009) Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 113:5720\u20135726. https:\/\/doi.org\/10.1182\/blood-2008-08-174946","journal-title":"Blood"},{"key":"6858_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/cells13070586","author":"M Prisciandaro","year":"2024","unstructured":"Prisciandaro M et al (2024) Stem cells collection and mobilization in adult autologous\/allogeneic transplantation: critical points and future challenges. Cells. https:\/\/doi.org\/10.3390\/cells13070586","journal-title":"Cells"},{"key":"6858_CR16","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.tmrv.2022.06.004","volume":"36","author":"I Garcia-Garcia","year":"2022","unstructured":"Garcia-Garcia I et al (2022) Comparison between standard and high dose of G-CSF for mobilization of hematopoietic progenitors cells in patients and healthy donors. Transfus Med Rev 36:159\u2013163. https:\/\/doi.org\/10.1016\/j.tmrv.2022.06.004","journal-title":"Transfus Med Rev"},{"key":"6858_CR17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/ajh.21569","volume":"85","author":"CD Fitzhugh","year":"2010","unstructured":"Fitzhugh CD et al (2010) Cardiopulmonary complications leading to premature deaths in adult patients with sickle cell disease. Am J Hematol 85:36\u201340. https:\/\/doi.org\/10.1002\/ajh.21569","journal-title":"Am J Hematol"},{"key":"6858_CR18","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/pr.2011.57","volume":"71","author":"T Daikeler","year":"2012","unstructured":"Daikeler T, Tichelli A, Passweg J (2012) Complications of autologous hematopoietic stem cell transplantation for patients with autoimmune diseases. Pediatr Res 71:439\u2013444. https:\/\/doi.org\/10.1038\/pr.2011.57","journal-title":"Pediatr Res"},{"key":"6858_CR19","unstructured":"https:\/\/www.mozobil.com. Mozobil (plerixafor) injection"},{"key":"6858_CR20","unstructured":"https:\/\/ www.aphexda.com. Aphexda, motixafortide for injection 36.5\u00a0mg\/mL"},{"key":"6858_CR21","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.bbmt.2017.04.007","volume":"23","author":"JT Stover","year":"2017","unstructured":"Stover JT, Shaw JR, Kuchibhatla M, Horwitz ME, Engemann AM (2017) Evaluation of hematopoietic stem cell mobilization rates with early plerixafor administration for adult stem cell transplantation. Biol Blood Marrow Transpl 23:1290\u20131294. https:\/\/doi.org\/10.1016\/j.bbmt.2017.04.007","journal-title":"Biol Blood Marrow Transpl"},{"key":"6858_CR22","doi-asserted-by":"crossref","unstructured":"Peter Abdelmessieh BB, Styler M, Khanal R, Ridgway F, Sorrentino M, Fung HC (2024) Asya Varshavsky-Yanovsky. in American Society of Hematology Vol. 144 Cell Collection and Manufacturing of HSPCs, CAR-T cells, and Other Cellular Therapy ProductsBlood, San Diego","DOI":"10.1182\/blood-2024-198457"},{"key":"6858_CR23","doi-asserted-by":"crossref","unstructured":"Crees ZD, Mark KS-G, Schroeder A (2023) Ravi Vij, Ella Sorani, Irit Gliko Kabir, Inbal Goldstein, Tzipi Lustig, Shaul Kadosh, John F. DiPersio. in American Society of Hematology Vol. 142(1) Cell Collection and ProcessingBlood, San Diego","DOI":"10.1182\/blood-2023-181452"},{"key":"6858_CR24","unstructured":"Close S et al (2025) Blood, Orlando,. in American Society of Hematology Vol. 146 4185"},{"key":"6858_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0287863","volume":"18","author":"DD Sukhtankar","year":"2023","unstructured":"Sukhtankar DD et al (2023) GPC-100, a novel CXCR4 antagonist, improves in vivo hematopoietic cell mobilization when combined with propranolol. PLoS One 18:e0287863. https:\/\/doi.org\/10.1371\/journal.pone.0287863","journal-title":"PLoS One"},{"key":"6858_CR26","doi-asserted-by":"crossref","unstructured":"Sukhtankar DD, Chin CTC, Ramos AC, Jhaver C, Caculitan KG, Cardarelli NG (2024) P. M. in American Society of Hematology Vol. 144Blood","DOI":"10.1182\/blood-2024-204101"},{"key":"6858_CR27","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1002\/cpdd.1302","volume":"12","author":"DD Sukhtankar","year":"2023","unstructured":"Sukhtankar DD, Chang LW, Tsai CY, Cardarelli PM, Caculitan NG (2023) Pharmacokinetics and pharmacodynamics of burixafor hydrobromide (GPC-100), a novel C-X-C chemokine receptor 4 antagonist and mobilizer of hematopoietic Stem\/Progenitor Cells, in mice and healthy subjects. Clin Pharmacol Drug Dev 12:1114\u20131120. https:\/\/doi.org\/10.1002\/cpdd.1302","journal-title":"Clin Pharmacol Drug Dev"},{"key":"6858_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7356","volume":"13","author":"X He","year":"2024","unstructured":"He X et al (2024) Predictive factors for peripheral blood stem cell mobilization in multiple myeloma in the era of novel therapies: a single-center experience. Cancer Med 13:e7356. https:\/\/doi.org\/10.1002\/cam4.7356","journal-title":"Cancer Med"},{"key":"6858_CR29","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/bmt.2012.281","volume":"48","author":"M Pozotrigo","year":"2013","unstructured":"Pozotrigo M et al (2013) Factors impacting stem cell mobilization failure rate and efficiency in multiple myeloma in the era of novel therapies: experience at Memorial Sloan Kettering Cancer Center. Bone Marrow Transplant 48:1033\u20131039. https:\/\/doi.org\/10.1038\/bmt.2012.281","journal-title":"Bone Marrow Transplant"},{"key":"6858_CR30","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1038\/leu.2012.323","volume":"27","author":"S Li","year":"2013","unstructured":"Li S, Fu J, Ma H, Mapara MY, Lentzsch S (2013) Lenalidomide-induced upregulation of CXCR4 in CD34+\u2009hematopoietic cells, a potential mechanism of decreased hematopoietic progenitor mobilization. Leukemia 27:1407\u20131411. https:\/\/doi.org\/10.1038\/leu.2012.323","journal-title":"Leukemia"},{"key":"6858_CR31","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1007\/s00277-025-06372-4","volume":"104","author":"S Kwon","year":"2025","unstructured":"Kwon S et al (2025) Impact of induction regimens on stem cell mobilization yields in newly diagnosed multiple myeloma. Ann Hematol 104:2297\u20132304. https:\/\/doi.org\/10.1007\/s00277-025-06372-4","journal-title":"Ann Hematol"},{"key":"6858_CR32","unstructured":"https:\/\/ www.neupogenhcp.com. Neupogen (filgrastim): Important safety information and indications"},{"key":"6858_CR33","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/bmt.2011.216","volume":"47","author":"K Hubel","year":"2012","unstructured":"Hubel K et al (2012) European data on stem cell mobilization with plerixafor in non-Hodgkin\u2019s lymphoma, Hodgkin\u2019s lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization. Bone Marrow Transplant 47:1046\u20131050. https:\/\/doi.org\/10.1038\/bmt.2011.216","journal-title":"Bone Marrow Transplant"},{"key":"6858_CR34","unstructured":"Plerixafor (ed) < https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/022311s023lbl.pdf"},{"key":"6858_CR35","doi-asserted-by":"publisher","unstructured":"Johnsrud A et al (2021) Stem cell mobilization in multiple myeloma: comparing safety and efficacy of cyclophosphamide +\/- plerixafor versus granulocyte Colony-Stimulating factor +\/- plerixafor in the Lenalidomide era. Transpl Cell Ther 27(590 e591\u2013590 e598). https:\/\/doi.org\/10.1016\/j.jtct.2021.04.016","DOI":"10.1016\/j.jtct.2021.04.016"},{"key":"6858_CR36","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.bbmt.2008.10.018","volume":"15","author":"DA Stewart","year":"2009","unstructured":"Stewart DA, Smith C, MacFarland R, Calandra G (2009) Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma. Biol Blood Marrow Transplant 15:39\u201346. https:\/\/doi.org\/10.1016\/j.bbmt.2008.10.018","journal-title":"Biol Blood Marrow Transplant"},{"key":"6858_CR37","doi-asserted-by":"publisher","first-page":"5210","DOI":"10.1182\/bloodadvances.2023010407","volume":"7","author":"ZD Crees","year":"2023","unstructured":"Crees ZD et al (2023) Hematopoietic stem cell mobilization for allogeneic stem cell transplantation by motixafortide, a novel CXCR4 inhibitor. Blood Adv 7:5210\u20135214. https:\/\/doi.org\/10.1182\/bloodadvances.2023010407","journal-title":"Blood Adv"},{"key":"6858_CR38","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1111\/trf.14182","volume":"57","author":"N Worel","year":"2017","unstructured":"Worel N, Frank N, Frech C, Fritsch G (2017) Influence of plerixafor on the mobilization of CD34+\u2009cell subpopulations and lymphocyte subtypes. Transfusion 57:2206\u20132215. https:\/\/doi.org\/10.1111\/trf.14182","journal-title":"Transfusion"},{"key":"6858_CR39","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1111\/trf.16424","volume":"61","author":"A Turunen","year":"2021","unstructured":"Turunen A et al (2021) Autograft cellular composition and outcome in myeloma patients: results of the prospective multicenter GOA study. Transfusion 61:1830\u20131844. https:\/\/doi.org\/10.1111\/trf.16424","journal-title":"Transfusion"},{"key":"6858_CR40","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1159\/000531940","volume":"50","author":"E Jantunen","year":"2023","unstructured":"Jantunen E, Partanen A, Turunen A, Varmavuo V, Silvennoinen R (2023) Mobilization strategies in myeloma patients intended for autologous hematopoietic cell transplantation. Transfus Med Hemother 50:438\u2013447. https:\/\/doi.org\/10.1159\/000531940","journal-title":"Transfus Med Hemother"},{"key":"6858_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1101495","volume":"14","author":"X Zhang","year":"2023","unstructured":"Zhang X, Zhang H, Lan H, Wu J, Xiao Y (2023) CAR-T cell therapy in multiple myeloma: current limitations and potential strategies. Front Immunol 14:1101495. https:\/\/doi.org\/10.3389\/fimmu.2023.1101495","journal-title":"Front Immunol"},{"key":"6858_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.568056","volume":"10","author":"T Mika","year":"2020","unstructured":"Mika T et al (2020) Altered T-lymphocyte biology following high-dose melphalan and autologous stem cell transplantation with implications for adoptive T-cell therapy. Front Oncol 10:568056. https:\/\/doi.org\/10.3389\/fonc.2020.568056","journal-title":"Front Oncol"},{"key":"6858_CR43","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/bjh.18831","volume":"202","author":"T Jo","year":"2023","unstructured":"Jo T et al (2023) Risk factors for CAR-T cell manufacturing failure among DLBCL patients: a nationwide survey in Japan. Br J Haematol 202:256\u2013266. https:\/\/doi.org\/10.1111\/bjh.18831","journal-title":"Br J Haematol"},{"key":"6858_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065688","author":"V Wittibschlager","year":"2023","unstructured":"Wittibschlager V (2023) CAR t-cell persistence correlates with improved outcome in patients with B-cell lymphoma. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24065688","journal-title":"Int J Mol Sci"},{"key":"6858_CR45","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.tmrv.2016.03.001","volume":"30","author":"A Fesnak","year":"2016","unstructured":"Fesnak A, Lin C, Siegel DL, Maus MV (2016) CAR-T cell therapies from the transfusion medicine perspective. Transfus Med Rev 30:139\u2013145. https:\/\/doi.org\/10.1016\/j.tmrv.2016.03.001","journal-title":"Transfus Med Rev"},{"key":"6858_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01193-6","volume":"14","author":"Z Tao","year":"2024","unstructured":"Tao Z et al (2024) Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies. Blood Cancer J 14:213. https:\/\/doi.org\/10.1038\/s41408-024-01193-6","journal-title":"Blood Cancer J"},{"key":"6858_CR47","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1182\/bloodadvances.2019000765","volume":"4","author":"JM Knight","year":"2020","unstructured":"Knight JM et al (2020) Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial. Blood Adv 4:467\u2013476. https:\/\/doi.org\/10.1182\/bloodadvances.2019000765","journal-title":"Blood Adv"},{"key":"6858_CR48","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/TA.0000000000000264","volume":"77","author":"LE Bible","year":"2014","unstructured":"Bible LE et al (2014) Early propranolol administration to severely injured patients can improve bone marrow dysfunction. J Trauma Acute Care Surg 77:54\u201360. https:\/\/doi.org\/10.1097\/TA.0000000000000264","journal-title":"J Trauma Acute Care Surg"},{"key":"6858_CR49","doi-asserted-by":"crossref","unstructured":"Aljawai Y et al (2025) in Blood 146(Suppl 1):1050","DOI":"10.1182\/blood-2025-1050"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06858-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06858-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06858-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:03:30Z","timestamp":1771949010000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06858-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":49,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["6858"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06858-9","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"assertion":[{"value":"27 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Burixafor was previously being developed by TaiGen Biotechnology Col Ltd. This work was supported by GPCR Therapeutics, Inc. and Exicure, Inc. DS, PC and NC are employees of GPCR Therapeutics USA, a subsidiary of Exicure, Inc. GK is a former employee of GPCR Therapeutics, Inc. LC and CT are employees of TaiGen Biotechnology Col Ltd and own company stock. Medical writing support was provided by Guissou Dabiri, PhD of GD Scientific & Medical Writing, LLC and was funded by GPCR Therapeutics, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial disclosure statement"}},{"value":"Financial Disclosure Statement: Burixafor was previously being developed by TaiGen Biotechnology Col Ltd. This work was supported by GPCR Therapeutics, Inc. and Exicure, Inc. DS, PC and NC are employees of GPCR Therapeutics USA, a subsidiary of Exicure, Inc. GK is a former employee of GPCR Therapeutics, Inc. LC and CT are employees of TaiGen Biotechnology Col Ltd and own company stock. Medical writing support was provided by Guissou Dabiri, PhD of GD Scientific & Medical Writing, LLC and was funded by GPCR Therapeutics, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"86"}}